2-溴-4-苯基丁酸甲酯 | 16503-47-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-溴-4-苯基丁酸甲酯
• 英文名称: methyl 2-bromo-4-phenylbutanoate
• 英文别名: α-Brom-γ-phenyl-buttersaeure-ethylester；2-bromo-4-phenyl-butyric acid methyl ester
• CAS: 16503-47-2
• 化学式: C₁₁H₁₃BrO₂
• 分子量: 257.127
• InChiKey: UIZZMKUFGKXJNR-UHFFFAOYSA-N

物化性质

• 沸点：
  298.4±28.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  2-溴-4-苯基丁酸甲酯 在 二异丁基氢化铝 作用下， 生成
  参考文献：
  名称：

  Privileged structure based ligands for melanocortin receptors—Substituted benzylic piperazine derivatives

  摘要：

  Replacement of the aryl piperazine moiety in compound I with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.018
• 作为产物：
  描述：

  4-苯基丁酸 在 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 氢溴酸 作用下， 生成 2-溴-4-苯基丁酸甲酯
  参考文献：
  名称：

  Privileged structure based ligands for melanocortin receptors—Substituted benzylic piperazine derivatives

  摘要：

  Replacement of the aryl piperazine moiety in compound I with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.018

文献信息

• 4-Hydroxythiazole inhibitors of 5-lipoxygenase
  作者：Francis A. J. Kerdesky、James H. Holms、Jimmie L. Moore、Randy L. Bell、Richard D. Dyer、George W. Carter、Dee W. Brooks

  DOI：10.1021/jm00111a035

  日期：1991.7

  identified as potent inhibitors of 5-lipoxygenase in vitro exhibiting IC50's of less than 1 microM. An investigation of structure-activity relationships showed that the most potent inhibitors of this series are the 5-phenyl derivatives. The corresponding thiazolidin-4-one analogues were found to be relatively inactive. The 4-hydroxythiazoles were active inhibitors against 5-lipoxygenase in both intact rat

  4-羟基噻唑已被确定为体外5-脂氧合酶的有效抑制剂，其IC50值小于1 microM。对结构活性关系的研究表明，该系列最有效的抑制剂是5-苯基衍生物。发现相应的噻唑烷丁-4-酮类似物相对没有活性。在完整的大鼠多形核白细胞和人全血中，4-羟基噻唑都是针对5-脂氧合酶的活性抑制剂。该化合物还是5-脂氧合酶的选择性抑制剂，对其他相关酶环氧合酶和12-和15-脂氧合酶的活性很弱。
• 3-heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1H)-quinolone
  申请人：Ciba-Geigy Corporation

  公开号：US05633379A1

  公开（公告）日：1997-05-27

  3-Heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1H)quinolone derivatives of formula I ##STR1## wherein the radicals R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently of the others hydrogen, an aliphatic hydrocarbon radical, free or etherified hydroxy, mercapto or etherified and/or oxidised mercapto, unsubstituted or aliphaticaliy substituted amino, nitro, free or esterified or amidated carboxy, cyano, free or amidated sulfamoyl, halogen or trifluoromethyl, X is oxy or optionally oxidised thio, A is a divalent aliphatic radical and R.sub.5 is an optionally partially hydrogenated aryl or heteroaryl radical that is unsubstituted or substituted by aliphatic or araliphatic hydrocarbon radicals, by free or etherified hydroxy, by mercapto or etherified and/or oxidised mercapto, by unsubstituted or aliphatically substituted amino, by aliphatic acyl, by free or esterified or amidated carboxy, by cyano, by free or amidated sulfamoyl, by halogen and/or by trifluoromethyl; free or etherified hydroxymethyl; cyano; or free or esterified or amidated carboxy, and tautomers and/or salts thereof, have antagonistic properties with respect to excitatory amino acids and can be used for the treatment of pathological conditions that are responsive to glycine-antagonistic blocking of NMDA-sensitive receptors.

  公式I中的3-杂原基脂肪基和3-杂原基（芳基）脂肪基-2（1H）喹啉衍生物，其中基团R1，R2，R3和R4各自独立地为氢，脂肪烃基，自由或醚化的羟基，巯基或醚化和/或氧化的巯基，未取代或脂肪基取代的氨基，硝基，自由或酯化或酰胺化的羧基，氰基，自由或酰胺化的磺酰基，卤素或三氟甲基，X为氧或可选的氧化硫，A为二价脂肪基，R5为可选部分氢化的芳基或杂芳基基团，未取代或取代为脂肪或芳基脂肪基，自由或醚化的羟基，巯基或醚化和/或氧化的巯基，未取代或脂肪基取代的氨基，脂肪酰基，自由或酯化或酰胺化的羧基，氰基，自由或酰胺化的磺酰基，卤素和/或三氟甲基；自由或醚化的羟甲基；氰基；或自由或酯化或酰胺化的羧基，以及其互变异构体和/或盐，对兴奋性氨基酸具有拮抗作用，并可用于治疗对甘氨酸-拮抗NMDA敏感受体的阻滞有反应的病理条件。
• Aminomethyl Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
  申请人：Coburn Craig A.

  公开号：US20080153846A1

  公开（公告）日：2008-06-26

  The present invention is directed to aminomethyl compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及氨甲基化合物，它们是β-分泌酶酶的抑制剂，并且在β-分泌酶酶参与的疾病的治疗中非常有用，例如阿尔茨海默病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在β-分泌酶酶参与的这些疾病的治疗中的用途。
• Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
  申请人：Merck, Sharp & Dohme Corp.

  公开号：US07820674B2

  公开（公告）日：2010-10-26

  The present invention is directed to aminomethyl compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及氨甲基化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病（如阿尔茨海默病）方面有用。本发明还涉及包含这些化合物的药物组合物以及在治疗β-分泌酶酶参与的这些疾病方面使用这些化合物和组合物。
• Nickel-Catalyzed Cross-Coupling of Acyl Chloride with Racemic α-Trifluoromethyl Bromide to Access Chiral α-Trifluoromethyl Ketones
  作者：Juanjuan Wu、Hongli Wu、Xinyu Liu、Yuekun Zhang、Genping Huang、Chun Zhang

  DOI：10.1021/acs.orglett.2c01208

  日期：2022.6.24

  The nickel-catalyzed reductive cross-coupling reaction of acyl chloride with racemic secondary α-trifluoromethyl bromide has been developed. By this chemistry, a series of structurally interesting chiral α-CF3 carbonyl compounds could be accessed with great enantioselectivity and good functional group tolerance. The study of late-stage transformation indicated that this chemistry could be used as the

  开发了镍催化酰氯与外消旋仲α-三氟甲基溴的还原交叉偶联反应。通过这种化学反应，可以得到一系列结构有趣的手性α-CF 3羰基化合物，具有很高的对映选择性和良好的官能团耐受性。后期转化的研究表明，这种化学方法可用作制备含有生物活性基序的产品的可靠方法。此外，对照实验已经说明了 α-三氟甲基对该反应的重要性。

表征谱图